730 related articles for article (PubMed ID: 11413536)
41. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
42. MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma.
De Sanctis V; Finolezzi E; Osti MF; Grapulin L; Alfò M; Pescarmona E; Berardi F; Natalino F; Moleti ML; Di Rocco A; Enrici RM; Foà R; Martelli M
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1154-60. PubMed ID: 18472357
[TBL] [Abstract][Full Text] [Related]
43. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
44. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96).
Koch P; Probst A; Berdel WE; Willich NA; Reinartz G; Brockmann J; Liersch R; del Valle F; Clasen H; Hirt C; Breitsprecher R; Schmits R; Freund M; Fietkau R; Ketterer P; Freitag EM; Hinkelbein M; Heinecke A; Parwaresch R; Tiemann M
J Clin Oncol; 2005 Oct; 23(28):7050-9. PubMed ID: 16129843
[TBL] [Abstract][Full Text] [Related]
45. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
46. Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
[TBL] [Abstract][Full Text] [Related]
47. International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients.
Navarro JT; Ribera JM; Oriol A; Vaquero M; Romeu J; Batlle M; Gómez J; Millá F; Feliu E
Haematologica; 1998 Jun; 83(6):508-13. PubMed ID: 9676023
[TBL] [Abstract][Full Text] [Related]
48. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
[TBL] [Abstract][Full Text] [Related]
49. [Prognostic analysis of patients with nasal-type NK/T-cell non-Hodgkin's lymphoma--a report of 93 cases].
Pan ZH; Huang HQ; Lin XB; Xia YF; Xia ZJ; Peng YL; Cai QQ; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2005 Dec; 24(12):1493-7. PubMed ID: 16351799
[TBL] [Abstract][Full Text] [Related]
50. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
[TBL] [Abstract][Full Text] [Related]
51. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol.
Atra A; Imeson JD; Hobson R; Gerrard M; Hann IM; Eden OB; Carter RL; Pinkerton CR
Br J Cancer; 2000 Apr; 82(8):1396-402. PubMed ID: 10780517
[TBL] [Abstract][Full Text] [Related]
52. Combined therapy in the treatment of primary mediastinal B-cell lymphoma: conventional versus escalated chemotherapy.
Avilés A; García EL; Fernández R; Gonzalez JL; Neri N; Díaz-Maqueo JC
Ann Hematol; 2002 Jul; 81(7):368-73. PubMed ID: 12185505
[TBL] [Abstract][Full Text] [Related]
53. Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma.
Niitsu N; Okamoto M; Aoki S; Okumura H; Yoshino T; Miura I; Hirano M
Ann Hematol; 2006 Jun; 85(6):374-80. PubMed ID: 16518603
[TBL] [Abstract][Full Text] [Related]
54. [Prognostic analysis of 62 cases of nasal NK/T-cell lymphoma].
Xiao J; Wang SS; Huang Y; Chen LK; Guan ZZ; Huang HQ; Xia ZJ; Xu RH; Lin TY
Ai Zheng; 2006 Sep; 25(9):1173-7. PubMed ID: 16965665
[TBL] [Abstract][Full Text] [Related]
55. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
56. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients.
Avilés A; Neri N; Huerta-Guzmán J
J Surg Oncol; 2002 Jun; 80(2):111-5. PubMed ID: 12173380
[TBL] [Abstract][Full Text] [Related]
57. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
58. Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma.
Kwon J; Kim IH; Kim BH; Kim TM; Heo DS
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):91-8. PubMed ID: 25721091
[TBL] [Abstract][Full Text] [Related]
59. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas.
Schlembach PJ; Wilder RB; Tucker SL; Ha CS; Rodriguez MA; Hess MA; Cabanillas FF; Cox JD
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1107-10. PubMed ID: 11072169
[TBL] [Abstract][Full Text] [Related]
60. Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study.
Cai L; Stauder MC; Zhang YJ; Poortmans P; Li YX; Constantinou N; Thariat J; Kadish SP; Nguyen TD; Kirova YM; Ghadjar P; Weber DC; Bertran VT; Ozsahin M; Mirimanoff RO
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):284-91. PubMed ID: 22079728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
